The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation.
BK polyomavirus
kidney
pediatrics
stem cell transplantation
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
received:
17
07
2019
accepted:
16
12
2019
pubmed:
19
12
2019
medline:
29
4
2021
entrez:
19
12
2019
Statut:
ppublish
Résumé
BK polyomavirus (BKPyV) is associated with symptomatic hemorrhagic cystitis after hematopoietic cell transplantation (HCT). Little is known about the host immune response, effectiveness of antiviral treatment, or impact of asymptomatic replication on long-term kidney function. In children and young adults undergoing allogeneic HCT, we quantified BKPyV viruria and viremia (pre-HCT and at Months 1-4, 8, 12, and 24 post-HCT) and tested associations of peak viremia ≥10 000 or viruria ≥109 copies/mL with estimated kidney function (glomerular filtration rate, eGFR) and overall survival at 2 years posttransplant. We examined the factors associated with viral clearance by Month 4, including BKPyV-specific T cells by enzyme-linked immune absorbent spot at Month 3 and cidofovir use. We prospectively enrolled 193 participants (median age 10 years) and found that 18% had viremia ≥10 000 copies/mL and 45% had viruria ≥109 copies/mL in the first 3 months post-HCT. Among the 147 participants without cystitis (asymptomatic), 58 (40%) had any viremia. In the entire cohort and asymptomatic subset, having viremia ≥10 000 copies/mL was associated with a lower creatinine/cystatin C eGFR at 2 years post-HCT. Viremia ≥10 000 copies/mL was associated with a higher risk of death (adjusted hazard ratio, 2.2; 95% confidence interval, 1.1-4.2). Clearing viremia was associated with detectable BKPyV-specific T cells and having viremia <10 000 copies/mL, but not cidofovir exposure. Screening for BKPyV viremia after HCT identifies asymptomatic patients at risk for kidney disease and reduced survival. These data suggest potential changes to clinical practice, including prospective monitoring for BKPyV viremia to test virus-specific T cells to prevent or treat BKPyV replication.
Sections du résumé
BACKGROUND
BK polyomavirus (BKPyV) is associated with symptomatic hemorrhagic cystitis after hematopoietic cell transplantation (HCT). Little is known about the host immune response, effectiveness of antiviral treatment, or impact of asymptomatic replication on long-term kidney function.
METHODS
In children and young adults undergoing allogeneic HCT, we quantified BKPyV viruria and viremia (pre-HCT and at Months 1-4, 8, 12, and 24 post-HCT) and tested associations of peak viremia ≥10 000 or viruria ≥109 copies/mL with estimated kidney function (glomerular filtration rate, eGFR) and overall survival at 2 years posttransplant. We examined the factors associated with viral clearance by Month 4, including BKPyV-specific T cells by enzyme-linked immune absorbent spot at Month 3 and cidofovir use.
RESULTS
We prospectively enrolled 193 participants (median age 10 years) and found that 18% had viremia ≥10 000 copies/mL and 45% had viruria ≥109 copies/mL in the first 3 months post-HCT. Among the 147 participants without cystitis (asymptomatic), 58 (40%) had any viremia. In the entire cohort and asymptomatic subset, having viremia ≥10 000 copies/mL was associated with a lower creatinine/cystatin C eGFR at 2 years post-HCT. Viremia ≥10 000 copies/mL was associated with a higher risk of death (adjusted hazard ratio, 2.2; 95% confidence interval, 1.1-4.2). Clearing viremia was associated with detectable BKPyV-specific T cells and having viremia <10 000 copies/mL, but not cidofovir exposure.
CONCLUSIONS
Screening for BKPyV viremia after HCT identifies asymptomatic patients at risk for kidney disease and reduced survival. These data suggest potential changes to clinical practice, including prospective monitoring for BKPyV viremia to test virus-specific T cells to prevent or treat BKPyV replication.
Identifiants
pubmed: 31851312
pii: 5680564
doi: 10.1093/cid/ciz1194
pmc: PMC7819507
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3044-3054Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK101600
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK093556
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001878
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Transplantation. 2017 Jun;101(6):1479-1487
pubmed: 27391197
J Clin Oncol. 2017 Nov 1;35(31):3547-3557
pubmed: 28783452
Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238
pubmed: 19747629
N Engl J Med. 2002 Aug 15;347(7):488-96
pubmed: 12181403
Sci Transl Med. 2014 Jun 25;6(242):242ra83
pubmed: 24964991
Biol Blood Marrow Transplant. 2011 Oct;17(10):1512-9
pubmed: 21385622
Blood. 2005 Aug 1;106(3):1130-2
pubmed: 15845896
Biol Blood Marrow Transplant. 2015 Jul;21(7):1284-90
pubmed: 25708219
Am J Transplant. 2007 Dec;7(12):2727-35
pubmed: 17908275
Am J Transplant. 2013 Mar;13 Suppl 4:179-88
pubmed: 23465010
Am J Transplant. 2017 Oct;17(10):2591-2600
pubmed: 28326672
Leuk Lymphoma. 2010 Jun;51(6):1055-62
pubmed: 20370539
Blood. 2017 Apr 20;129(16):2316-2325
pubmed: 28209721
Biol Blood Marrow Transplant. 2014 Dec;20(12):2056-61
pubmed: 25038395
Biol Blood Marrow Transplant. 2009 Sep;15(9):1038-1048.e1
pubmed: 19660716
J Clin Oncol. 1995 May;13(5):1103-9
pubmed: 7738616
Clin Infect Dis. 2007 Mar 15;44(6):830-7
pubmed: 17304456
J Pediatric Infect Dis Soc. 2015 Jun;4(2):134-42
pubmed: 26407413
Transpl Infect Dis. 2017 Dec;19(6):
pubmed: 28865164
Eur J Haematol. 2017 Jun;98(6):632-634
pubmed: 28083990
Clin Infect Dis. 2018 Jan 18;66(3):368-375
pubmed: 29020348
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
Biol Blood Marrow Transplant. 2014 Aug;20(8):1204-10
pubmed: 24769326
PLoS Pathog. 2019 Jan 8;15(1):e1007505
pubmed: 30620752
Am J Transplant. 2011 Nov;11(11):2443-52
pubmed: 21831150
Kidney Int. 2012 Aug;82(4):445-53
pubmed: 22622496
Blood. 2014 Jul 24;124(4):645-53
pubmed: 24876561
J Antimicrob Chemother. 2018 Jan 1;73(1):12-21
pubmed: 29190347
Transpl Infect Dis. 2015 Apr;17(2):234-41
pubmed: 25648430
JAMA. 2014 Jun 25;311(24):2518-2531
pubmed: 24892770